Regeneron

Most people have questions about #ClinicalTrials. Fewer realize just how much control participants actually have. Understanding the process is the first step to considering participation.     Explore the facts at bit.ly/4m2e215 

Today we announced positive data from our Phase 3 trial evaluating our investigational siRNA therapeutic in generalized myasthenia gravis (#gMG) were published in The Lancet Group and presented at the American Academy of Neurology Annual Meeting.    Learn more about our novel approach and these important findings. 🧠 https://bit.ly/4tSNh3A    #AAN2026  

🔬 What do you see?    Hint: These branching shapes help scientists study how the body communicates, revealing connection in motion. 

Episode 2 of our Regeneron Scientific Journey series opens the lab door to the real work that turns biology into potential medicines. From target identification and assay design to in vivo studies and preclinical validation, the episode follows our teams as they make data-driven decisions at each step.   See how our teams connect deep expertise in biology with platform technologies to advance the strongest pipeline candidates with speed and rigor.   Watch now: https://bit.ly/4mjhypr

Published today in Nature Portfolio: Regeneron Genetics Center researchers analyzed more than 1 million genomes, including about 250,000 from non-European ancestry backgrounds, and found that genetic repeat expansions linked to neurological disease like Huntington’s Disease are more widespread than previously recognized. In some cases, MRI-detected brain atrophy appears years before symptoms.     Learn more about how these findings could help identify risk earlier and potentially open the door to earlier intervention: https://bit.ly/4tikaXH

We’re announcing a new collaboration with TriNetX to support Regeneron’s capabilities in drug discovery and development, as well as new initiatives to deliver digital health solutions of the future.     The collaboration will expand Regeneron’s world-leading genomic and proteomic EHR-linked database by accessing TriNetX’s data network of approximately 300 million de-identified and anonymized patients.     Read our press release to learn more: https://bit.ly/41bdUEE

As we enter our next decade as the title sponsor of Regeneron Science Talent Search (STS), we’re reflecting on the incredible journeys of STS winners from the past ten years, and the impact on the future of scientific advancement. 🎓 These remarkable young scientists continue to shape the world in ways that inspire us every day. STS, a program of Society for Science, is the nation’s oldest and most prestigious science and technology competition for high school students. Here’s to the leaders, explorers, and problem solvers who started their journey at STS and brilliant scientific leaders to come.    #RegeneronSTEMFueled 

Throwback to 2013. We aimed to sequence 100,000 exomes in five years through the work of Regeneron Genetics Center, then one of the largest efforts in the world.     Over a decade later, that first milestone looks more like a starting line. We’ve since surpassed 3 million exomes sequenced.    The technology has advanced. The collaborations have expanded. The datasets have grown. What remains constant is why we do it: ground discovery in human genetics so we can advance science and deliver better medicines to patients. 

Why do people join #ClinicalTrials? For many, it’s about improving their lives.    Start your journey at https://bit.ly/4m2e215

🔬 What are you looking at?      Hint: This image wasn’t captured by a camera. It was created using AI that turns scientific data into vivid visuals—helping Regeneron scientists see biology in new ways.